VivoSim Labs (VIVS) Competitors $1.79 -0.04 (-2.37%) As of 12:24 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock VIVS vs. PRPH, MRKR, RVPH, MTEX, LPCN, QTTB, CARM, CASI, GELS, and HOTHShould you be buying VivoSim Labs stock or one of its competitors? The main competitors of VivoSim Labs include ProPhase Labs (PRPH), Marker Therapeutics (MRKR), Reviva Pharmaceuticals (RVPH), Mannatech (MTEX), Lipocine (LPCN), Q32 Bio (QTTB), Carisma Therapeutics (CARM), CASI Pharmaceuticals (CASI), Gelteq (GELS), and Hoth Therapeutics (HOTH). These companies are all part of the "pharmaceutical products" industry. VivoSim Labs vs. Its Competitors ProPhase Labs Marker Therapeutics Reviva Pharmaceuticals Mannatech Lipocine Q32 Bio Carisma Therapeutics CASI Pharmaceuticals Gelteq Hoth Therapeutics ProPhase Labs (NASDAQ:PRPH) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability. Does the media favor PRPH or VIVS? In the previous week, ProPhase Labs and ProPhase Labs both had 1 articles in the media. ProPhase Labs' average media sentiment score of 1.87 equaled VivoSim Labs'average media sentiment score. Company Overall Sentiment ProPhase Labs Very Positive VivoSim Labs Very Positive Which has more volatility & risk, PRPH or VIVS? ProPhase Labs has a beta of -0.41, indicating that its share price is 141% less volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Do insiders and institutionals hold more shares of PRPH or VIVS? 9.5% of ProPhase Labs shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by company insiders. Comparatively, 3.7% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, PRPH or VIVS? VivoSim Labs has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$6.77M2.37-$53.36M-$1.26-0.31VivoSim Labs$140K33.27-$2.48M-$10.20-0.18 Is PRPH or VIVS more profitable? ProPhase Labs has a net margin of 0.00% compared to VivoSim Labs' net margin of -1,725.00%. VivoSim Labs' return on equity of -46.87% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets ProPhase LabsN/A -184.38% -64.59% VivoSim Labs -1,725.00%-46.87%-28.62% SummaryVivoSim Labs beats ProPhase Labs on 6 of the 11 factors compared between the two stocks. Get VivoSim Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for VIVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIVS vs. The Competition Export to ExcelMetricVivoSim LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.66M$2.92B$5.56B$9.26BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.1820.2728.5819.56Price / Sales33.27298.79434.47183.65Price / CashN/A43.1536.0257.93Price / Book0.327.668.165.58Net Income-$2.48M-$55.11M$3.24B$257.82M7 Day Performance-5.46%0.03%-0.64%-0.39%1 Month Performance16.38%7.47%4.93%7.80%1 Year PerformanceN/A-3.28%26.04%12.95% VivoSim Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIVSVivoSim LabsN/A$1.79-2.4%N/AN/A$4.66M$140K-0.1820Positive NewsPRPHProPhase Labs0.5379 of 5 stars$0.43-1.8%N/A-87.1%$18.36M$6.77M-0.34130Positive NewsGap DownMRKRMarker Therapeutics4.4868 of 5 stars$1.60+1.9%$13.17+722.9%-71.8%$17.76M$6.59M-1.2060RVPHReviva Pharmaceuticals3.2231 of 5 stars$0.38+2.6%$9.00+2,289.8%-68.1%$17.61MN/A-0.485Positive NewsHigh Trading VolumeMTEXMannatech1.3706 of 5 stars$8.41-8.6%N/A+14.8%$17.49M$117.87M-84.10250Positive NewsGap DownLPCNLipocine3.0093 of 5 stars$3.14+1.0%$9.00+186.6%-58.0%$16.64M$11.20M-3.0810QTTBQ32 Bio2.6783 of 5 stars$1.39+2.2%$12.17+775.3%-91.9%$16.59M$1.16M-0.2839CARMCarisma Therapeutics3.0084 of 5 stars$0.40+1.8%$1.93+378.9%-67.5%$16.51M$19.63M-0.2620Positive NewsCASICASI Pharmaceuticals4.2313 of 5 stars$1.41+5.7%$4.00+184.7%-79.2%$16.34M$28.54M-0.55180Gap DownGELSGelteqN/A$1.90+13.8%N/AN/A$15.76M$100K0.00N/AGap DownHOTHHoth Therapeutics3.273 of 5 stars$1.30+10.2%$4.00+207.7%+52.3%$15.59MN/A-1.144 Related Companies and Tools Related Companies ProPhase Labs Alternatives Marker Therapeutics Alternatives Reviva Pharmaceuticals Alternatives Mannatech Alternatives Lipocine Alternatives Q32 Bio Alternatives Carisma Therapeutics Alternatives CASI Pharmaceuticals Alternatives Gelteq Alternatives Hoth Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIVS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VivoSim Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VivoSim Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
